Seres Therapeutics, Inc. (MCRB) Fair Value 2026

MCRB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (49/100)

Quick Summary — As of 2026-08-28, Seres Therapeutics, Inc. (MCRB) trades at $5.11, versus a $3.40 median fair value across its 2 active models — 33.4% below the current price. QOC: 5.1/10. Value Trap Risk: 49/100 (WARN). 2/13 models active.

Key Facts

Ticker
MCRB
Price
$5.11
Quality Score
5.1/10
Value Trap Risk
49/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Value Trap score of 49 suggests caution despite apparent undervaluation

Is Seres Therapeutics, Inc. (MCRB) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Seres Therapeutics, Inc. (MCRB) appears overvalued as of : the median of 2 independent fair value estimates is $3.40, 33.4% below the current price of $5.11. Estimates range from $2.50 to $4.31. MCRB scores 5.1/10 on fundamental quality and 49/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. MCRB’s -33.4% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Seres Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give MCRB?

2 Intrinsic Value Models vs. Current Price ($5.11)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $2.50 -51.2%
Option-Based · Low Conviction
 $4.31 -15.7%

All Models Active

All 2 models are displayed above.

What Is Seres Therapeutics, Inc. (MCRB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Seres Therapeutics, Inc.'s intrinsic value is estimated at $3.40. Trading at its current price of $5.11, the valuation engine raises significant caution: 2 of 2 models flag downside risk, projecting a median implied return of -33.4%. Notably, PWERM sees the most upside at -15.7% (fair value: $4.31), while Regime Cross is the most conservative at -51.2% ($2.50). The spread between these extremes — +35.5% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About MCRB?

2 of 13 models are currently active for MCRB. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for MCRB is $3.40 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does MCRB Rank in Biotechnology?

Among 625 Biotechnology stocks, MCRB ranks #286 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Seres Therapeutics, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is MCRB a Value Trap?

CirclFi's Value Trap algorithm assigns MCRB a score of 49/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Seres Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Seres Therapeutics, Inc. scores 5.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +35.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MCRB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MCRB's 2 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Seres Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

GDTCCytoMed Therapeutics LimitedQOC 5.1CELUCelularity Inc.QOC 5.1LGVNLongeveron Inc.QOC 5.1KAPAKairos Pharma, Ltd.QOC 5.1DMACDiaMedica Therapeutics Inc.QOC 5.1ORICORIC Pharmaceuticals, Inc.QOC 5.1HINDVyome Holdings, Inc.QOC 4.5WINTWindtree Therapeutics, Inc.QOC 3.0CLDXCelldex Therapeutics, Inc.QOC 6.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: GDTC · CELU · LGVN · KAPA · DMAC · ORIC · HIND · WINT · CLDX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MCRB?

4 companies across all industries closest to MCRB’s Quality of Company score of 5.1/10.

IXHLIncannex Healthcare Inc.QOC 5.1FCUVFocus Universal Inc.QOC 5.1JAGUJaguar Uranium Corp.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: IXHL · FCUV · JAGU · NVDA

Where Does MCRB Sit in CirclFi's Biotechnology Rankings?

MCRB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Seres Therapeutics, Inc.’s Valuation?

What is Seres Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Seres Therapeutics, Inc. (MCRB)'s intrinsic value at $3.40 — the median of 2 independent model estimates as of 2026-08-28, ranging from $2.50 to $4.31. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MCRB overvalued or undervalued right now?

At $5.11, 0 of 2 active models suggest MCRB may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $3.40, 33.4% below the current price of $5.11 — a consensus view that MCRB is overvalued. The assessment depends on which methodology best fits Seres Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for MCRB?

Seres Therapeutics, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MCRB?

CirclFi analyzes MCRB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is MCRB a value trap in 2026?

Seres Therapeutics, Inc.'s Value Trap score is 49/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Seres Therapeutics, Inc. (MCRB) has a median fair value of $3.40 — 33.4% below the current price of $5.11 — as of 2026-08-28.” Source: circlfi.com/stock/MCRB/ · Methodology
Primary sources for this MCRB valuation
  • Financial statements: Seres Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001609809) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MCRB as of ; valuations recomputed .